Medicare AdvantageCoverageHigh impact
[New York] Carelon Medical Benefits Management Clinical Appropriateness Guidelines updates
Anthem BCBS·NY · Oncology, Hematology, Orthopedics +6 more·Provider Bulletin
Effective date
Nov 15, 2026
We identified it
Aug 2, 2026
Summary
Carelon Medical Benefits Management updated clinical appropriateness guidelines effective November 15, 2026, with significant expansions to genetic/molecular testing coverage for multiple cancer types, new approved drugs (imlunestrant, niraparib, dordaviprone, tovorafenib), and standardized orthopedic surgery requirements (12-week conservative management). Key changes include expanded breast cancer molecular testing to earlier stages, new prostate/thyroid cancer testing criteria, and updated musculoskeletal surgery pre-operative requirements.
Action Required
By November 15, 2026: Billing and clinical teams must implement the following changes: (1) Update prior authorization templates and medical necessity criteria in billing software to reflect expanded genetic/molecular testing indications for breast cancer (stages IIB, IIIA, IIIB, IIIC), prostate cancer (all metastatic cases), thyroid cancer (remove gene restrictions), and other cancer types listed; (2) Add new drug therapies to treatment protocol lists requiring testing: imlunestrant (breast cancer), niraparib and talazoparib (prostate cancer), dordaviprone (gliomas), tovorafenib (pediatric gliomas); (3) Update orthopedic pre-operative documentation requirements to enforce 12-week minimum conservative management before shoulder/hip/knee arthroplasty and arthroscopy; (4) Modify rejection logic to deny claims for non-medically necessary tests including WES/WGS/WTA, RNA fusion/expression analysis via ctRNA, ctHPV DNA in oropharyngeal carcinoma, NIFTP somatic testing, and gene expression testing in Waldenström macroglobulinemia; (5) Providers must document medical necessity for all molecular testing per new 'clinical utility' requirement; (6) Update EMR templates for cancer cases to capture new testing indications and clinical scenarios. Failure to comply will result in claim denials for services not meeting updated guidelines.